Cytokinetics Company Description
Cytokinetics studies the cytoskeleton to get to the heart of the problem. The biopharmaceutical firm's development pipeline includes a lead drug candidate -- in oral and intravenous formulations -- designed for the treatment of heart failure based on a cytoskeletal protein in the heart muscle. It is being developed in collaboration with Amgen. Several other candidates are targeting multiple types of cancer; early clinical trials of these anti-cancer candidates were supported by GlaxoSmithKline and the National Cancer Institute. Cytokinetics is responsible for additional clinical development but may seek future strategic alliances to help advance this set of drugs into later-stage trials.
View the Comprehensive Company Description for Cytokinetics
The Company Description provides a historical perspective of Cytokinetics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Cytokinetics's evolution in the marketplace.
